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Background: Intravenous antibiotics for pulmonary exacerbations (PEs) of cystic ﬁbrosis (CF) usually target Pseudomonas aeruginosa. Insights into
the CF lung microbiome have questioned this approach. We used RT-qPCR to determine whether intravenous antibiotics reduced P. aeruginosa
numbers andwhether this correlated with improved lung function.We also investigated antibiotic effects on other common respiratory pathogens in CF.
Methods: Sputa were collected from patients when stable and again during a PE. Sputa were expectorated into a RNA preservation buffer for RNA
extraction and preparation of cDNA. qPCR was used to enumerate viable P. aeruginosa as well as Streptococcus pneumoniae, Haemophilus
influenzae, Staphylococcus aureus, Burkholderia cepacia complex and Aspergillus fumigatus.
Results: Fifteen CF patients were followed through 21 PEs.A complete set of serial sputum samples was unavailable for two patients (three separate PEs).
P. aeruginosa numbers did not increase immediately prior to a PE, but numbers during intravenous antibiotic treatment were reduced≥4-log in 6/18 and
≥1-log in 4/18 PEs. In 7/18 PEs, P. aeruginosa numbers changed very little with intravenous antibiotics and one patient demonstrated a≥2-log increase
in P. aeruginosa load.H. influenzae and S. pneumoniaewere detected in ten and ﬁve PEs respectively, but with antibiotic treatment these bacteria rapidly
became undetectable in 6/10 and 4/5 PEs, respectively. There was a negative correlation between P. aeruginosa numbers and FEV1 during stable phase
(rs = 0.75, p b 0.05), and reductions in P. aeruginosa load with intravenous antibiotic treatment correlated with improved FEV1 (rs = 0.52, p b 0.05).
Conclusions: Exacerbations are not due to increased P. aeruginosa numbers in CF adults. However, lung function improvements correlate with
reduced P. aeruginosa burden suggesting that current antibiotic treatment strategies remain appropriate in most patients. Improved understanding
of PE characterised by unchanged P. aeruginosa numbers and minimal lung function improvement following treatment may allow better targeted
therapies.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Cystic fibrosis is a multi-organ genetic disorder characterised
by chronic pulmonary sepsis that leads to eventual lung
destruction and premature death. Survival in countries with
well-developed health services has increased substantially over⁎ Corresponding author at: Department of ThoracicMedicine, The Prince Charles
Hospital, Rode Road, Chermside, Brisbane 4032, Queensland, Australia. Tel.: +61
731396394.
E-mail address: David_Reid@health.qld.gov.au (D.W. Reid).
1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.03.008the past three decades as a consequence of earlier diagnosis,
specialised care delivered by multi-disciplinary teams, attention to
nutrition and judicious use of antibiotics to delay and suppress
chronic infection, interspersed with periods of more intensive
intravenous antibiotic therapy to treat “acute pulmonary exacer-
bations” [1,2]. Pulmonary exacerbations (PE) are characterised by
worsening respiratory symptoms with increased cough and
production of more purulent sputum, often accompanied by
systemic upset [3]. They are associated with accelerated lung
function decline and impose a significant burden on the patient's
quality of life and healthcare resources [3–5].by Elsevier B.V. All rights reserved.
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although acute viral infections may play a role in children [6,7].
In adults with established chronic bacterial infection, respiratory
viruses probably have less of a role. Instead, changes in numbers
of the usual predominant bacterium, Pseudomonas aeruginosa,
in conjunction with increased intensity of the host immune
response have been considered the primary cause for PE [8],
although recent data based on 16S ribosomal DNA sequencing
have questioned this supposition [9,10]. Antibiotic treatment for
CF exacerbations usually targets P. aeruginosa in adult patients,
which generally results in clinical improvements following
two-weeks of at least two intravenous antibiotics from different
classes, although a number of factors have been identified that
may predict for treatment failure [11]. Studies using microbio-
logical culture-based methods have variably reported changes in
P. aeruginosa numbers following intravenous antibiotics, with
reductions in bacterial load more apparent in children than adults,
which may reflect the severity of disease and chronicity of
infection [12–15]. This has led to the view that P. aeruginosa is
the primary cause of PE. However this view is not convincingly
supported by available data and the role of other bacterial
pathogens also needs to be considered, as the polymicrobial
nature of lung infection in CF becomes increasingly apparent
[16–18]. In this study, we utilised reverse transcription
quantitative polymerase chain reaction (RT-qPCR) to quantify
P. aeruginosa numbers in CF sputum and to identify the presence
of other common bacterial and fungal pathogens such as
Staphylococcus aureus, Haemophilus influenzae, Burkholderia
cepacia complex, Steptococcus pneumoniae and Aspergillus
fumigatus. We followed 15 individual adult CF patients infected
with P. aeruginosa through 21 exacerbation episodes to test our
hypothesis that clinical improvement following aggressive
antibiotic therapy would be associated with a reduction in
P. aeruginosa numbers.
2. Methods
2.1. Subjects and sample collection
Patients attending the Adult CF Unit at the Royal Hobart
Hospital (Tasmania, Australia) were eligible for inclusion in the
study. Ethics approval was obtained (Southern Tasmanian Health
and Medical Research Ethics Committee, H9813) and all patients
(or guardians for those aged less than 18 years) gave written
consent prior to commencement of the study. Between April 2008
and February 2010 sputum was collected where possible from all
adolescent and adult patients attending routine outpatient clinic
visits when “stable” and then again during an in-patient treatment
episode for a PE. During a PE, sputum was obtained within 72 h
of admission (to capture patients admitted during weekends) and
multiple samples were collected during the admission up until the
day of discharge. Day 0 represents the first day of the admission
prior to the administration of intravenous antibiotics. Although
procurement of sputum was undertaken up until day three of
the admission, sputum was obtained prior to the first dose of
intravenous antibiotic in 10 exacerbations, after two or less
antibiotic doses in six exacerbations and in four exacerbations,sputumwas obtained on day two when patients had received up to
six antibiotic doses.
The sputum samples were spontaneously expectorated
directly into a sterile 70 mL specimen container (for routine
microbiological culture), or into a 20 mL aliquot of RNAlater
(Qiagen) for RT-qPCR analysis. After storage at 4 °C for a few
days samples were transferred to a −20 °C freezer until required
for transcript analysis. During 11 separate PE episodes, sputum
samples were also colour coded for “purulence” using an
in-house scoring system and according to the following scheme:
White or clear only = 0; cream = 1; yellow = 2; mostly yellow,
some green = 3; mostly green, some yellow = 4; green = 5;
beige/brown = 6.
In three exacerbation episodes in two patients, we only
obtained sputum samples over the first few days of the PE; one
patient (subject 3—second exacerbation episode) took one's
own discharge on day three of treatment and in the subsequent
(third) admission, the patient continued one's intravenous
antibiotic treatment at home in a remote outreach setting
following six days in hospital, which meant sputum collection
only occurred over the first six days; the other patient (subject
4) who was treated at home with intravenous antibiotics for a
mild PE, was unable to provide sputum samples after day four
because of rapid clinical improvement and complete resolution
of cough and sputum.
Antibiotic susceptibility of P. aeruginosa isolates from
routinely collected sputum samples was determined against
five different classes of antimicrobials (β-lactams, β-lactam +
inhibitor combination, monobactams, aminoglycosides and
fluoroquinolones), using the method described by the Clinical
Laboratory and Standards Institute [19]. P. aeruginosa ATCC
27853 was used as the control strain, as recommended by the
NCCLS. Multi-antibiotic resistance was defined as resistance to
all agents in two or more of the following antibiotic classes;
β-lactams, aminoglycosides and fluoroquinolones, according to
the US CF Foundation Consensus Guidelines [20].
The full methods for molecular bacterial and fungal
enumeration, as well as primer validation and standard curves
are provided in the Supplementary material (Fig. 1a–g).
2.2. Primers used in this study
Primers used to enumerate microorganisms have been
previously published. P. aeruginosa (psd7 for and rev, targeting
16S rRNA) [22] andH. influenzae (Hi for and rev, targeting 23S)
[21,23], S. pneumoniae (HexA-S and HexA-AS) [24] targeting a
mismatch repair system, S. aureus (gyrU and gyrL) [25] targeting
DNA gyrase, B. cepacia complex (CeMuVi-16-2 and Eub-16-1)
[26] targeting 16S rRNA and A. fumigatus (28S-466 and
28S-533) [27] targeting 28S rRNA. To validate their specificity
primers were examined against genomic DNA (extracted using
the UltraCleanMicrobial DNA Isolation Kit MolBio), and cDNA
(generated as described below) from several species/clinical
isolates of each organism, amplicon size estimated and
representative amplicons sequenced (AGRF, Melbourne, data
not shown). In addition, the 100% specificity of the primers for
P. aeruginosawas validated using 32 serial sputum samples from
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conventional culture (data not shown).
2.3. RNA isolation from sputum
RNAlater was removed from sputum by gentle dabbing with
sterile filter paper whilst the sputum sample was situated in a
sterile Petri dish. RNA was then extracted in Tri Reagent® from
0.01 to 0.15 g portion of purulent plugs (free of saliva) as detailed
above for microbial cultures.
2.4. Reverse transcription of RNA
cDNAwas generated (20 μL reactions) from RNA essentially
as described in the SuperScript® III First-Strand Synthesis
SuperMix (Invitrogen) kit using a mixture of random hexamers
and oligo(dT)20 for priming. RNAwas removed with 1 μL of the
kit supplied RNAase. Each 20 μL of cDNA was diluted with
46.7 μL of water before qPCR.
2.5. Quantitative real time PCR (qPCR)
Duplicate real-time PCR reactions were set up with 10 μM
of each primer according to the Platinum® SYBR® Green
qPCR SuperMix-UDG (Invitrogen) kit instructions, using a
CAS-1200 liquid pipetting robot (Corbett Life Science,
Australia). Product amplification was carried out using the
following conditions, enzyme activation (2 min at 50 °C),
initial denaturation (2 min at 95 °C), thermocyling (40 cycles
of melting at 15 s at 95 °C, annealed at 30 s and extended 30 s
at 72 °C). Data were collected at 72 °C. The annealing
temperatures used in this study were 62, 54, 54, 50, 54, and
60 °C for P. aeruginosa, S. aureus, Burkholderia cepacia
complex, S. pneumoniae, H. influenzae, and A. fumigatus,
respectively. Melt curve analysis of each sample was under-
taken to confirm the specificity of the PCR products by heating
from 70 to 95 °C at a linear rate of 0.5 °C/s. Excitation
wavelength was 470 nm, with detection wavelength set at
510 nm. A calibrator and no-template control were included in
each assay for each primer set. The calibrator consisted of CF
sputum cDNA that showed expression of P. aeruginosa 16S
rRNA and/or gDNA from the particular microbial species being
assayed.
2.6. Confirmation of absence of gDNA contamination of RNA
isolated from sputum
An aliquot of all RNA from sputum samples was analysed
by qPCR, without prior reverse transcription, to confirm
the absence of contaminating gDNA using the primer set for
P. aeruginosa 16S rRNA.Fig. 1. Examples of the three different patterns of change in P. aeruginosa numbers o
P. aeruginosa numbers (shaded columns) and sputum purulence (clear columns) by
experience any reduction in P. aeruginosa load or sputum purulence (purulence score
episodes; (c) subject 1 experienced a reduction in P. aeruginosa load by day 3, but n
have a pre-exacerbation sample available. Sputum purulence was not scored for sub3. Data analysis
3.1. Criteria for inclusion of RT-qPCR data
Presence of transcripts in sputum samples was defined as
detection in technical replicate qPCRs of the same cDNA
sample and appropriate Ct and melt analysis. Only Ct values
between 6 and 31 were accepted for analysis, as assays with all
primer sets on a dilution series of P. aeruginosa genomic DNA
showed only Ct values within this range were quantitatively
valid. If a product amplified in the RNA-only control,
indicating gDNA contamination, within 3 cycles of the cDNA
product or with a Ct of b30 then the sample was excluded from
analysis.
3.2. Enumeration of microorganisms
The geometric mean of the absolute expression of
each target gene (performed in duplicate) was used for
enumeration. Microorganism numbers were then calculated
from the standard curves using Rotorgene 6 software,
version 6.1 (Corbett Life Science, Australia). The standard
curves were firstly adjusted using the Ct of the calibrator.
Bacteria were enumerated per gramme of sputum (colony
forming units per gramme of sputum, CFU/g). A.
fumigatus was quantified as the mycelial mass per gramme
of sputum (AfMM/g).
2.3. Statistical analyses
The values for CFU/g and AfMM/g of sputum were log
transformed prior to analysis. Daniel's XL toolbox (version 2.66,
http://xltoolbox.sourceforge.net) was used to test the significance
of the regression analyses. Wilcoxon's rank test was used to
follow changes in P. aeruginosa numbers during PEs. Correla-
tions between variables were assessed using Spearman's rank
co-efficient. Where possible, to determine the effects of
antibiotics on bacterial load during treatment of a PE, we took
the average log of the first two bacterial cell counts obtained
during the first 72 h of admission (usually obtained prior to the
first antibiotic dose and repeated 24 h later) when available and
compared this to the average log of the bacterial cell counts from
the last two consecutive sputum samples obtained within 72 h of
discharge. If consecutive bacterial counts were not available on
admission or over the last two days of the treatment course, the
first and last sputum samples were used to determine changes in
bacterial numbers. A one-tailed p b 0.05 was considered
statistically significant for antibiotic treatment effects. To
compare the relative reductions in P. aeruginosa with relative
changes in lung function following intravenous antibiotics we
determined the proportion of viable bacteria remaining at the endbserved with antibiotic treatment; (a) subject 6 experienced a rapid reduction in
day 3, which was maintained until the end of treatment; (b) subject 7 did not
s not illustrated) with antibiotic treatment during three consecutive exacerbation
umbers had increased almost back to baseline values by day 8. Subject 7 did not
ject 1.
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CFU/g at the end of treatment/P. aeruginosaCFU/g at the start of
treatment).4. Results
4.1. Demographic data and number of exacerbations followed
during study
Demographic data are provided in Table 1 and antibiotic
treatment regimes for each patient are given in Table S1. The
antibiotics used for maintenance during stable phase were the
ones being taken at the time of sampling. For patients being
treated with intravenous antibiotics for an exacerbation, the
antibiotics were the ones administered for the duration of the
treatment period. We prospectively recruited 15 CF patients
chronically infected with P. aeruginosa and followed them
through 21 PEs over a 23-month period. A PE was defined
according to the criteria of Rosenfeld et al in all patients except
for subject 2 who was treated with intravenous antibiotics
electively prior to a holiday (“tune up”). One patient (subject 14)
satisfied the criteria of Rosenfeld and colleagues [28], but the
treatment course was primarily directed at eradication of
P. aeruginosa following first isolation. Eighteen of the PE
treatment periods were followed through the entire treatment
course for more than seven days (median length of treatment;
LOT 14 days, range 7–28 days). A total of 136 sputum samples
were obtained over the surveillance period. In nine exacerbation
episodes we had available at least one stable sputum sample
obtained within three months prior to the exacerbation treatment
course. Four patients were followed through more than one
exacerbation episode. The usual oral and inhaled antibiotic
regimes used by the patients when well, routine microbiological
culture and antibiotic sensitivity results at the onset of PE and the
intravenous antibiotic agents used to treat the PE are provided in
the supplementary table (Table S1).Table 1
Clinical demographics of the study population when stable during the preceding six
Age Gender CFTR mutation 1 CFTR mutation
Subject 1 35 M pheF508del pheF508del
Subject 2 26 M pheF508del pheF508del
Subject 3 54 M p.Gly542X ?
Subject 4 26 F pheF508del pheF508del
Subject 5 25 F pheF508del N1303K
Subject 6 21 M pheF508del pheF508del
Subject 7 24 F pheF508del pheF508del
Subject 8 20 F pheF508del pheF508del
Subject 9 29 F pheF508del 1898 + 1G ≥ A
Subject 10 19 M R553X 1717-1G ≥ A
Subject 11 18 M pheF508del pheF508del
Subject 12 20 M pheF508del ?
⁎Subject 13 18 M pheF508del pheF508del
Subject 14 23 M pheF508del pheF508del
Subject 15 20 M pheF508del V520F
⁎ This patient had no contact with the clinical team for 12 months and lung funct
exacerbation. FEV1—forced expiratory volume in one second; FVC—forced vital c4.2. Clinical outcomes
Clinical improvement in terms of reduced symptoms was
subjectively experienced by all of the patients in the study by the
end of the intravenous antibiotic treatment course. Improvement
was accompanied by an overall decrease in sputum purulence and
an increase in FEV1 in 15 of the 17 exacerbation episodes that
were followed for more than seven days and where repeat sputum
samples and matched lung function results were available
(Table 2). In two PE episodes, lung function was not available
on admission. The first patient (subject 8) had associated
abdominal pain (second admission) and the other patient (subject
10) presented with severe pleuritic chest pain, which limited their
ability to perform respiratory manoeuvres.
4.3. Presence of non-Pseudomonad pathogens by RT-qPCR
Non-P. aeruginosa pathogens that we elected to assess in
sputum (based on representative bacterial and fungal pathogens
frequently isolated on routine culture) were present far less
frequently than P. aeruginosa in our patient population. Of the
136 sputum samples collected there were 136 (100%), 40 (29%),
28 (21%), 21 (15%) detections by RT-qPCR of P. aeruginosa,
H. influenzae, A. fumigatus and S. pneumoniae, respectively.
B. cepacia complex and S. aureus were detected in 12 (10%) and
6 (5%) of 115 samples tested; molecular detection was
discontinued for these organisms because of the low rate of
routine culture isolation of Bcc in the Tasmanian CF population
and the poor sensitivity of the S. aureus qPCR (see below).
S. pneumoniae was most frequently detected by RT-qPCR in the
co-presence of H. influenzae (n = 19 sputum detections),
and very rarely detected in the absence of H. influenzae (two
sputum samples only). In contrast, H. influenzae was detected by
RT-qPCR in 21 sputa where there was no evidence of co-existing
S. pneumoniae. The non-Pseudomonad bacterial pathogens were
detected in much lower numbers than P. aeruginosa during a PE
(Table 3) and there was no relationship between the numbers ofmonths, including known CFTR mutations.
2 FEV1 (Litres) FEV1% FVC (Litres) FVC% BMI
1.95 55 3.81 93 20.1
2.77 65 4.06 81 21.5
1.91 48 2.39 48 19.3
2.62 88 3.41 99 23.6
1.77 56 2.44 67 19.6
2.67 64 3.91 80 20.3
1.14 36 1.88 62 19.5
1.88 63 2.67 78 18.8
2.32 70 3.04 80 18.9
2.43 60 3.79 81 18.4
3.89 93 5.51 112 19.8
3.27 75 4.36 85 20.9
4.05 102 5.14 108 20.2
4.06 97 4.95 101 25.1
3.17 80 4.73 102 18.6
ion shown is based on spirometry performed 12 months prior to pulmonary
apacity; BMI—body mass index. ? unknown allelic mutation.
Table 2
Lung function indices at the commencement (baseline) and at the end (post), of an antibiotic treatment course for a PE.
FEV1 base FEV1 post FEF25-75 base FEF25–75 post FVC base FVC post LOT Δ P. aeruginosa (log-reduction)
Subject 1 1.51 1.90 0.58 0.59 3.09 4.01 14 −2.49
Subject 2 2.85 2.87 1.74 1.98 3.99 3.89 10 −0.31
Subject 3 1.28 1.99 1.21 0.78 1.63 3.58 10 −5.49
Subject 3 a 1.90 1.87 1.30 0.86 2.75 3.16 10 a −5.91
Subject 3 1.71 1.67 1.16 1.31 1.71 1.67 6 0.85
Subject 4 b 1.73 1.68 0.75 0.74 2.74 2.84 10 b 3.34
Subject 5 1.72 1.68 1.04 0.72 2.48 2.70 16 0.01
Subject 6 1.59 2.79 0.68 1.66 2.91 4.06 14 −7.55
Subject 7 1.12 1.17 0.59 0.54 1.65 1.79 10 −0.42
Subject 7 0.85 1.13 0.30 0.43 1.13 1.46 14 0.02
Subject 7 0.84 1.12 0.33 0.43 1.35 1.78 14 3.33
Subject 8 0.94 1.29 – −0.51 1.69 1.99 ?7 −0.64
Subject 8 c – 1.14 – 0.42 – 2.08 18 −3.71
Subject 9 1.85 2.13 1.19 1.26 2.63 3.05 28 −4.71
Subject 9 1.93 2.18 1.31 1.51 2.72 3.0 12 −2.25
Subject 10 d – 1.36 – 0.47 – 2.51 7 −4.66
Subject 11 3.79 4.02 5.32 5.42 2.60 3.23 13 −2.71
Subject 12 2.32 3.4 1.46 1.98 3.37 4.85 14 −6.29
Subject 13 1.38 2.04 0.7 1.13 2.34 3.16 7 −1.05
Subject 14 3.94 4.17 3.92 4.53 4.86 4.99 23 −3.5
Subject 15 1.32 2.26 0.61 0.89 2.88 4.26 9 −3.4
Base; lung function on admission (measured in litres). Post; lung function at discharge. FEF 27–75; forced expiratory flow between 25% and 75% of FVC. LOT =
length of treatment; total days of intravenous antibiotics course.
a Sputa only available over ﬁrst three days, but LOT 10 days.
b Sputa only available over ﬁrst three days, but LOT 10 days.
c Abdominal pain precluded lung function on admission.
d No lung function on admission because of pleuritic chest pain.
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shown).
4.4. Routine culture versus RT-qPCR for detection of pathogens
There were 20 time-matched sputum samples available for
routine culture and antibiotic sensitivity testing as well as for
molecular detection of respiratory pathogens. These samples were
matched by patient and day and were usually obtained at exactly
the same time, whereby the patient was asked to first expectorate
into a routine sterile collection sputum pot for conventional
sputum culture and then into a separate pot containing RNAlater
formolecular enumeration. All of the sputum samples in this study
assessed by routine culture (non-quantitative) were positive for the
presence of P. aeruginosa and 100% of the corresponding
RNAlater samples were also positive by RT-qPCR.H. influenzae
was detected by RT-qPCR in eight samples, but was not isolated
from any of these sputa by routine culture. S. pneumoniae was
detected in seven samples by RT-qPCR, but was not isolated by
routine culture in any of the samples. A. fumigatus was present in
four samples by both routine culture and RT-qPCR, but a further
two culture negative samples were positive by RT-qPCR.
B. cepacia complex was not detected in any sample by routine
culture, but was detected by RT-qPCR in 10 sputum samples from
four patients who had no history of previous Bcc isolation on
routine culture. Methicillin-resistant S. aureus (MRSA) was
isolated by routine bacterial culture in four sputum samples (all
from the same patient), but S. aureus was not detected by
RT-qPCR in any of these matched samples indicating that theS. aureus primers used were unable to detect MRSA. However,
RT-qPCR detected S. aureus in four samples from three patients
where there was not a matched routine culture result available and
2/3 of these patients had isolated S. aureus or MRSA on routine
culture in the recent past. Reactions from all samples where
pathogens were detected by RT-qPCR but not by routine culture
were further analysed by agarose gel electrophoresis to confirm
amplification of a product of the correct size (data not shown).
Melting curve analysis was performed and confirmed that the
correct product was amplified (data not shown).
4.5. Changes in P. aeruginosa load during treatment of a PE
Overall, there was a significant reduction in sputum
P. aeruginosa numbers between the first 48 h of the admission
and the last 48 h of the treatment course; median CFU/g
sputum decreasing from 1.0 × 108 CFU/g (range 1.8 × 103–
3.2 × 109 CFU/g) to median 9.1 × 105 CFU/g (range
1.2 × 101–3.1 + 109 CFU/g, p = 0.005; Table 3). However,
closer analysis revealed three different patterns of change: in 6/18
exacerbations where patients were followed for more than seven
days, there was a ≥ four-log reduction and in 4/18 treatment
courses there was a ≥one-log reduction in P. aeruginosa
numbers from the beginning to the end of the exacerbation
episode (Tables 2 & 3). In 7/18 exacerbations there was no
reduction in P. aeruginosa numbers (fold change of bone log,
either up or down) and in one patient, P. aeruginosa numbers
increased significantly (subject 7, third admission). Representative
examples of changes in P. aeruginosa numbers during intravenous
Table 3
Changes in bacterial numbers with antibiotic treatment and the presence of antibiotic multi-drug resistant (MDR) P. aeruginosa strains.
MDR P. aeruginosa
CFU/g stable
Days
pre-acute
P. aeruginosa
CFU/g acute
P. aeruginosa
CFU/g post
H. influenzae
CFU/g acute
H. influenzae
CFU/g post
S. pneumoniae
CFU/g acute
S. pneumoniae
CFU/g post
Subject 1 No 2.3 × 109 −32 4.8 × 108 3.6 × 107 ND ND ND ND
Subject 2 No 2.2 × 109 −170 1.8 × 109 7.9 × 108 5.4 × 102 2.4 × 102 9.2 × 103 3.4 × 103
Subject 3 Yes NA – 1.0 × 108 2.8 × 103 LLD ND ND ND
Subject 3 a No NA – 4.1 × 108 NA ND ND ND ND
Subject 3 – NA – 3.7 × 108 1.4 × 109 1.1 × 104 1.5 × 102 ND ND
Subject 4 a Yes 4.8 × 104 −55 5.9 × 103 NA LLD ND ND ND
Subject 5 Yes 5.5 × 109 −20 5.6 × 108 2.6 × 109 1.2 × 102 1.2 × 102 ND ND
Subject 6 No 2.7 × 108 −40 3.6 × 108 1.2 × 101 6.2 × 103 ND 3.5 × 103 ND
Subject 7 No 9.9 × 108 −55 1.3 × 109 1.5 × 109 9.9 × 104 ND 2.4 × 104 ND
Subject 7 No NA – 3.2 × 109 3.1 × 109 ND ND ND ND
Subject 7 No NA – 1.8 × 103 8.1 × 107 ND ND ND ND
Subject 8 No NA – 8.9 × 106 2.4 × 107 ND ND ND ND
Subject 8 No 1.1 × 108 −47 1.4 × 107 2.6 × 107 ND ND ND ND
Subject 9 b Yes NA – 1.2 × 109 3.2 × 104 ND ND 4.9 × 105 ND
Subject 9 b No 2.5 × 106 −21 3.9 × 105 3.8 × 103 ND ND ND ND
Subject 10 No NA – 7.3 × 105 16 × 101 ND ND ND ND
Subject 11 No NA – 1.0 × 108 1.5 × 101 LLD ND ND ND
Subject 12 No 4.79 × 108 −70 1.9 × 108 2.0 × 101 5.6 × 105 ND ND ND
Subject 13 No NA – 1.6 × 106 9.1 × 105 5.1 × 105 ND ND ND
Subject 14 c No 8.9 × 106 −26 4.3 × 104 1.4 × 101 9.4 × 104 1.1 × 104 7.1 × 104 ND
Subject 15 No 1.7 × 106 −37 2.6 × 104 1.3 × 101 ND ND ND ND
MDR; multi-drug resistant P. aeruginosa strain, NA; not available, ND; not detected, LLD; lower limit of detection of RT-qPCR. Days pre-acute; the number of days
pre-exacerbation that the most recent stable sputum sample was obtained.
a These two subjects were followed for only the ﬁrst three and four days of the antibiotic course, respectively.
b Patient was pregnant at the time of sampling.
c This patient had isolated P. aeruginosa for the ﬁrst time and was undergoing an eradication treatment course.
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followed through more than one exacerbation episode, the
reduction in numbers was variable between exacerbations and
was not related to antibiotic resistance profiles (see supplementary
data) or to the antibiotics administered. Subject 7 was followed
through three successive exacerbations within a seven-month
period and demonstrated no real change in bacterial load in the first
two treatment episodes and then a substantial increase in
P. aeruginosa numbers (≥ four-fold) during the third antibiotic
treatment course. This patient had very severe lung disease
requiring frequent intravenous antibiotic courses and went on to
undergo lung transplantation soon after the study was finished.
There was no statistical relationship between change in
P. aeruginosa numbers and length of intravenous antibiotic
treatment.
4.6. P. aeruginosa antibiotic resistance profile and response to
antibiotic therapy
Most patients had a combination of mucoid and non-mucoid
P. aeruginosa strains isolated from sputum. Four exacerbation
episodes in three patients were associated with at least one
multi-drug resistant strain of P. aeruginosa. Two patients
(subjects 3 & 9) experienced greater than two-log reduction in
P. aeruginosa numbers despite the presence of at least one strain
displaying antibiotic multi-resistance, although one patient
(subject 5) demonstrated no change and in one patient (subject
7; third consecutive admission), there was a 3.3 log increase in
P. aeruginosa numbers.4.7. Changes in non-Pseudomonad pathogens during treatment
for a PE
H. influenzae was detected by RT-qPCR in 11 PE episodes in
10 patients and S. pneumoniae was detected in five patients on
admission for a PE. H. influenzae became undetectable in 10/11
PEs (nine patients) followed for more than seven days of
intravenous antibiotic treatment and S. pneumoniae became
undetectable in 4/5 PEs (five patients) by the end of the
intravenous antibiotic course. A. fumigatus was detected by
RT-qPCR in sputum at the commencement of treatment during
five exacerbation episodes in four patients. In 4/5 of
the exacerbation episodes, A. fumigatus remained detectable in
the majority of serial sputum samples up until the end of the
treatment period, which is perhaps not surprising as none of the
patients received anti-fungal agents or were treated with
corticosteroids during the exacerbation episode (data not shown).
4.8. Relationship between sputum purulence and P. aeruginosa
numbers
There was an overall significant positive correlation between
sputum purulence and P. aeruginosa numbers (rs = 0.67,
p b 0.0001; Fig. 2). However, despite this relationship there
was still a wide range of P. aeruginosa numbers within each
purulence score suggesting that purulence is not solely related to
the amount ofP. aeruginosa present. Sputum purulence generally
reduced with treatment over the time course of an exacerbation as
the patient clinically improved (Fig. 1c as an example of this). On
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purulence, only for purulence to increase over the subsequent
early days of treatment with an accompanying increase in
bacterial load. However, sputum purulence generally reduced in
most patients with parallel reductions in P. aeruginosa numbers.
There was no relationship between the enumeration of the other
pathogens assessed and sputum purulence, which was probably
not unexpected given the lower levels of detection.
4.9. Relationship between lung function and P. aeruginosa
numbers
There was a significant negative correlation between
P. aeruginosa numbers and FEV1% predicted when patients
were sampled during stable phase (Fig. 3a, rs = 0.75, p = 0.02),
but this relationship was not evident at the commencement of
treatment for a PE. The proportion of persisting P. aeruginosa
bacteria following treatment when expressed as a percentage of
the original CFU/g of viable organisms was negatively correlated
with changes in FEV1 and FEF25–75 (rs = 0.52 and rs = 0.57,
p b 0.05, respectively), i.e. those patients who experienced the
greatest decreases in P. aeruginosa counts by RT-qPCR were the
ones who experienced the largest improvements in FEV1
(Fig. 3b). There was also a strong negative correlation between
the proportion of persisting detectable P. aeruginosa and end of
treatment FEV1 whether expressed as an absolute value (rs =
0.71, p b 0.001), or percentage of predicted (rs = 0.57, p b 0.05)
at the end of the treatment course (Fig. 3c).
5. Discussion
The use of quantitative PCR targeted to bacterial DNA to
quantify bacteria is well established. A potential disadvantage of
that approach is that it may detect non-viable bacterial cells, forFig. 2. The correlation between sputum purulence and quantitative load of Pexample during or following antibiotic treatment. The short
half-life of RNA molecules, i.e. 6.8 min for messenger RNA in
Escherichia coli [29], means that detection of RNA molecules is
much less likely to detect non-viable bacteria, and the high
copy number of RNA transcripts gives the potential for high
sensitivity in detecting bacteria. This is the first study to use
molecular methods based on RNA to prospectively follow viable
P. aeruginosa numbers over close interval periods during
antibiotic treatment for a PE in adult patients with cystic fibrosis.
Using molecular methods based on ribosomal RNA, we
demonstrate that intravenous antibiotics reduce P. aeruginosa
numbers in just over half of patients, but that reductions in
P. aeruginosa numbers and improved lung function are strongly
associated. In a third of patients there was no real change in
P. aeruginosa numbers by the end of targeted anti-P. aeruginosa
treatment and these patients were the ones who derived the least
improvement in lung function. Changes in bacterial load with
antibiotic treatment were unrelated to P. aeruginosa antibiotic
susceptibility profiles and some patients with multi-resistant
strains on admission still demonstrated substantial P. aeruginosa
load reductions.
Pulmonary exacerbations in CF are associated with significant
morbidity and accelerated lung function loss, but the causal
mechanism is poorly understood [3,30]. Antibiotic treatment for
exacerbations is empirically directed against P. aeruginosa, which
is considered to be the dominant pathogen in the CF lung.
Although patients usually respond clinically, a reduction in
P. aeruginosa numbers and airway inflammation has not been
consistently demonstrated in adults with established CF lung
disease [31,32]. It has also previously been noted that antimicro-
bial sensitivity profiles based on planktonic P. aeruginosa cultures
are not predictive of reductions in bacterial load in vivo or clinical
response and it is likely that some of the bacterial load reductions
observed in our patients represented antibiotic effects against. aeruginosa in 10 patients followed through a total of 12 exacerbations.
Fig. 3. The correlation between; (a) P. aeruginosa numbers and lung function when stable pre-exacerbation; (b) reduced P. aeruginosa numbers (expressed as a
proportion of the numbers present at the onset of PE) and improvements in lung function with intravenous antibiotics and; (c) the proportion of persisting
P. aeruginosa and absolute FEV1 at the end of intravenous antibiotic treatment. Only those data from patients who provided sputum samples over more than seven
days of treatment are presented.
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bacterial loads of P. aeruginosa using RT-qPCR with the number
of viable organisms per g of CF sputum being in the order of 109
during exacerbations. Higher numbers of P. aeruginosa were
associated with poorer lung function. Such a high burden of
infection will exceed the phagocytic capacity of airway neutro-
phils, which are usually present in the order of 106 to 107 cells per
g of CF sputum [35]. There was no suggestion that P. aeruginosa
numbers had increased immediately prior to, or at the time of, PE
in those patients where a sputum sample was available at a stable
time-point before the PE. These findings are consistent with a
study undertaken by Stressmann and colleagues in which serial
sputum samples were collected over several weeks leading up to a
PE [10]. Their study quantified P. aeruginosa by qPCR of
genomic DNA, excluding DNA released from dead organisms,
and found similar P. aeruginosa numbers to those in our study
[10]. The aetiology of exacerbations in CF may therefore not be
directly related to increases in P. aeruginosa numbers per se but
potentially to changes in bacterial behaviour and/or the dynamics
of how the various constituents of the complex bacterial
communities interact with one another.
In a follow-up to their pre-exacerbation study, using the same
patients, Stressmann and colleagues also collected sputum samples
following onset of the index PE [9]. In this more recent analysis,
the relative abundance of P. aeruginosa increased compared to
non-Pseudomonad species following antibiotic therapy [9], but
there was no quantitative assessment of actual changes in
P. aeruginosa density during treatment. The latter would have
allowed comment on whether the apparent increase in abundance
of P. aeruginosa simply represented more marked antibiotic
effects on non-Pseudomonads compared to P. aeruginosa or to
true increases in P. aeruginosa numbers (see comments below).
Our novel data demonstrating a relationship between reductions in
P. aeruginosa numbers and improvements in lung function with
aggressive antibiotic therapy in adults with CF suggest that
successful P. aeruginosa killing is probably the main contributor
to the clinical response, at least in terms of improved lung function
[14]. Interestingly, the 12 patients studied by Stressmann and
Daniels had more severe lung disease compared to our study
population, although the age range was very similar. It is possible
that conventional antibiotics have progressively lesser effects
against P. aeruginosa in CF as lung disease severity and the need
for intravenous antibiotic courses increases. The serial PE data
from subject 7 who experienced no real change in P. aeruginosa
numbers during three exacerbation episodes and went on to
undergo lung transplantation would support this. However, no
definitive conclusion can be made on this issue from our study or
indeed from that of Daniels et al, particularly given the single
agent oral, dual agent oral and combination oral and intravenous
antibiotic regimes used to treat PEs in their study, but the
magnitude of bactericidal effects with intravenous antibiotics and
possibly the length of treatment in patients with severe lung disease
warrants further investigation.
Patients in our study generally experienced clinical benefit in
terms of reduced symptoms and sputum purulence by the end of
their treatment course, but a third demonstrated very little in the
way of improvement in lung function or consistent change inP. aeruginosa numbers. There are very few studies in adult
patients with CF that have demonstrated a significant correlation
between alterations in P. aeruginosa numbers and improved lung
function following antibiotic treatment. The data that are
available to suggest a direct link come from studies undertaken
mainly in children and conducted using conventional culture-
dependent quantitative load determinations [15,36]. However,
the situation in adults with CF is very different to that in children,
as individuals receiving intravenous antibiotics will frequently
have severe lung disease and P. aeruginosa strains with a
different phenotype to those isolated from young patients.
Furthermore, P. aeruginosa strains from adult patients exhibit
increased antibiotic resistance and treatment regimens may
need to be more aggressive, involving more than two
anti-Pseudomonad antibiotics. It may also be necessary to
consider additional agents that target bacteria such as
anaerobes and emerging data suggest these pathogens may be
particularly relevant in older patients with more severe disease
[34,37,38]. Although we did not specifically quantify anaer-
obes, our RT-qPCR analyses revealed the presence of other
pathogens such as H. influenzae, S. pneumoniae and
A. fumigatus, but most of these organisms were not detected
on routine laboratory culture. Unfortunately, our primers for
S. aureus performed poorly and were neither specific nor
sensitive and these factors are very important if molecular
detection methods are to replace routine culture for rapid
identification and enumeration of pathogens. However, the
advantage of our approach is that we immediately placed
sputum samples into RNA preservative buffer and used reverse
transcription to generate cDNA, which ensured that we only
amplified genes from viable bacteria or fungi during qPCR.
Other studies have used DNA in frozen sputum samples to
enumerate bacterial pathogens, which carries the risk as noted
by Rogers et al of quantifying dead bacteria as well as living
cells especially during periods of intensive antibiotic therapy
[39].
The majority of the other bacterial pathogens we identified
became undetectable by RT-qPCR following intravenous
antibiotics and “eradication” of H. influenzae was accompanied
by reductions in P. aeruginosa, whereas the three patients with
persisting H. influenzae at the end of intravenous antibiotics
experienced no reductions in P. aeruginosa numbers (data not
shown). H. influenzae and S. pneumoniae were present in much
lower numbers than P. aeruginosa. Interestingly, S. pneumoniae
was frequently detected in the co-presence of H. influenzae, but
was very infrequently found in the absence of H. influenzae,
which may suggest potential complex interplays between these
bacterial species in the respiratory tract of CF patients. In vitro
and animal studies suggest that H. influenzae may induce a host
immune response at mucosal surfaces to S. pneumoniae and
produce toxins (bacteriocins) that interfere with S. pneumoniae
survival, but these inter-species interactions and the clinical
implications have to date not been explored in CF [40,41].
A potential confounder that needs to be considered when
following bacterial loads during an exacerbation is the anatomical
site in the CF airway that the sputum sample originated from.
Sputum purulence in individual patients was sometimes variable
698 D.W. Reid et al. / Journal of Cystic Fibrosis 12 (2013) 688–699from day to day, although it was clear that overall bacterial
numbers generally reduced in most patients as purulence
lessened. However, in this study there was a small group of
patients who experienced an early reduction in sputum purulence
and bacterial counts only for numbers to progressively increase
again after the initial few days of treatment. An explanation for
this observation may be that antibiotic resistant clones proliferate
to fill the niche following killing of antibiotic sensitive strains
early on in the antibiotic treatment course. Further research will
be needed to distinguish these possibilities.
In summary, we have used an accurate molecular approach to
quantify P. aeruginosa numbers in chronically infected adult CF
patients and demonstrated a negative correlation between
bacterial load and lung function in stable patients. Improved
lung function during antibiotic treatment for a PE was associated
with a significant reduction in P. aeruginosa numbers suggesting
targeting P. aeruginosa remains an appropriate management
approach in most adult patients with mild-to-moderate disease.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2013.03.008.
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